ESCAPE Bio Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, announced that Julie Anne Smith, Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16th at 2:40 p.m. Eastern Time.
Presentation Details
Date: Monday, November 16, 2020
Time: 2:40 p.m. ET
URL to Access Webcast: https://wsw.com/webcast/stifel27/esbi/2073328
About ESCAPE Bio
ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases. ESB1609 is in a Phase 1 multiple ascending dose study in healthy volunteers. ESCAPE has advanced a mutant-selective LRRK2 G2019S kinase inhibitor for Parkinson’s Disease (PD) patients to IND-enabling studies. A pharmacologic structure corrector of Alzheimer’s patients carrying the ApoE4 risk allele is in Discovery. For additional information, please visit www.escapebio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005303/en/
Source: ESCAPE Bio Inc.
View this news release online at:
http://www.businesswire.com/news/home/20201112005303/en
